Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Vomiting 1Osteoarthritis 1Nausea 1Cancer Pain 1Breast Neoplasms 1Adenomatous Polyposis Coli 1

Interventions

Letrozole 20Docetaxel 16Cyclophosphamide 13Zoledronic Acid 12exemestane 11Trastuzumab 11Anastrozole 11Paclitaxel 10Tamoxifen 9Capecitabine 9Fulvestrant 8Epirubicin 8pegfilgrastim 7pertuzumab 6liposomal doxorubicin 6abemaciclib 6Saline Solution 6palbociclib 5Sodium Chloride 5Dexmedetomidine 5Carboplatin 5Bupivacaine 5Bevacizumab 5ribociclib 4pegylated granulocyte colony-stimulating factor 4eribulin 4Tranexamic Acid 4Standard of Care 4Pamidronate 4Filgrastim 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Breast Neoplasms × Duration of Therapy × Clear all
NCT00092183 2017-05-05

An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)

Merck Sharp & Dohme LLC

Phase 4 Completed
866 enrolled
Breast

Breast Neoplasms, Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡